AD-GL0002

Drug Profile

AD-GL0002

Latest Information Update: 25 May 2006

Price : $50

At a glance

  • Originator ActinoDrug Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Liver disorders; Parkinson's disease

Most Recent Events

  • 25 May 2006 No development reported - Preclinical for Parkinson's disease in Germany (unspecified route)
  • 25 May 2006 No development reported - Preclinical for Liver disorders in Germany (unspecified route)
  • 25 May 2006 No development reported - Preclinical for Cancer in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top